Skip Navigation



QJM Advance Access published online on May 6, 2005
QJM, doi:10.1093/qjmed/hci066
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
98/6/427    most recent
hci066v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Baskar, V.
Right arrow Articles by Singh, B.M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baskar, V.
Right arrow Articles by Singh, B.M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press on behalf of the Association of Physicians. All rights reserved. For Permissions, please email: journals.permissions@oupjournals.org
Received November 23, 2004
Revised March 17, 2005

Original article

Hypertension-based clinical risk strategies for detecting microalbuminuria in diabetes

V. Baskar 1*, D. Kamalakannan 1, B. Kiberd 2, M.R. Holland 1, and B.M. Singh 1

1 From the Wolverhampton Diabetes Centre, New Cross Hospital, Wolverhampton, UK
2 From the Dalhousie University, Nova Scotia, Canada

* To whom correspondence should be addressed.
V. Baskar, E-mail: baskar{at}doctors.org.uk


  Abstract

Background: Microalbuminuria screening to identify patients at risk of diabetic nephropathy is widely accepted.

Aim: To investigate whether blood-pressure-based strategies can identify such patients without the need for microalbuminuria testing.

Methods: Spot urine for albumin/creatinine ratios was performed in all patients over an 18-month period. The performance of four combinations of clinical models, based on existing triggers for anti-hypertensive intervention (prior use and/or existing systolic BP exceeding 140 or 160 mmHg and/or dipstick proteinuria exceeding 1+ or 2+) was evaluated at microalbuminuria thresholds of 3.5 and 10 mg/mmol. The models were ranked 1 to 4, based on their escalating relative strengths in predicting need for intervention.

Results: Of 3748 patients, 1257 (34%) or 739 (20%) exceeded microalbuminuria thresholds of 3.5 or 10 mg/mmol. All four models predicted microalbuminuria risk (areas under ROC curves 0.60-0.77, all p < 0.001). The models (1-4) identified 2220, 2465, 2803 or 2937 for intervention, respectively, irrespective of microalbuminuria status, and missed 368, 232, 194 or 126 at 3.5 mg/mmol and 164, 87, 81 or 45 at 10 mg/mmol.

Discussion: Clinical models using routinely measured parameters reduced the target population for microalbuminuria screening by 60-80%, missing 3-10% of patients with albumin/creatinine ratios exceeding 3.5 mg/mmol or 1-4% of those exceeding 10 mg/mmol.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.